Google Inc. (NDAQ:GOOG) insiders continue to sell stock at an astonishing rate (according to their Form 4 filings with the SEC), having unloaded nearly $1.7 billion during the past six months alone. Topping the list are Lawrence Page with $312,482,000 in sales along with Eric Schmidt with $290,538,000 in sales, both during just the past six months. There is a debate on Wall Street as to whether or not this kind of selling can be justified as "diversification" or whether it constitutes a negative sentiment on the company - after all, if insiders were confident in their company's future, why would they be selling? Warren Buffet has 99% of his net worth tied into Berkshire, while Bill Gates has the vast majority of his money tied up in Microsoft... why should Google be any different?

The fact is that even after over two years of being public, Google still tops the insider selling list on Wall Street, without a single purchase during recent months. Many maintain that the insiders are merely diversifying their holdings by selling Google stock and buying other companies. In reality, this type of diversification is typically of companies that have recently gone public; however, the selling usually subsides after the first year or so. If we look at Microsoft, Cisco, and other large companies, we can certainly see some spending; however, these companies pale in comparison to Google. Microsoft has only experienced sales of $500,000,000 during the past six months, while Cisco recorded under $100,000,000. While many experts cannot agree what the insider selling means, it would be difficult to argue that they are not significant.

Wouldn't it be interesting to see how a CEOs pay measures up to an average workers'? Well, a report put out by the Economic Policy Institute does just that! The 2005 study found that the CEO of a company making at least $1 billion in annual revenues made $10,982,000, compared to the average workers' $41,861. Amazingly, the average worker made $377 less than the average CEO made in an hour! The study also found that CEO pay increased an amazing 82% between 2000 and 2005, while the average workers' pay declined by 0.3%. This inbalance in pay has caused an uproar in Corporate America, as an increasing number of people question whether or not such large compensation packages are really needed to attract and retain talent.

These people are quick to criticize CEO pay, saying that it is a problem that boils down to basic corporate governance. They acknowledge that CEO pay is determined by the Board of Directors (a group voted in by shareholders); however, in two-thirds of all companies the CEO also serves as Chairman of the Board, which is clearly a conflict of interest. Moreover, the company often has extensive control over who is nominated to the Board of Directors. Only in extreme cases do majority shareholders get a seat on the Board; rather, the Board is most often hand-picked by management. And even if shareholders do wish to nominate other candidates, there are often large costs associated with the proxy process with no guarantees of success.

Who is this hurting? In the end, shareholders are most often left footing the bill. In addition to actual company money being spent on compensation, investors must also deal with the dilution of stock options and grants (often given as incentive). With the recent stock option backdating scandals hitting the market, this issue is being pressed even further. These people suggest that companies should work to tie CEO compensation packages closer to company performance, while also maintaining an independent Board of Directors to eliminate any conflict of interest.

Bristol-Myers Squibb (NYSE:BMY) announced today that CEO Peter Dolan will leave the position of chief executive officer, effective immediately. This announcement stems from the recommendation of a court-appointed monitor to the Board that Mr. Dolan and General Counsel Richard Willard be dismissed from the company because of their failed efforts to protect sales of the company's drug Plavix. This latest accusation is only one in a long string of corporate mishaps for Mr. Dolan and the company's management.

The troubles began in 2005 when the company became embroiled in an accounting scandal. Federal prosecutors were concerned that the company was engaging in an illegal practice known as "channel stuffing" by providing wholesalers with more product than they could sell in order to inflate the company's income and earnings. Since any federal indictments would have caused substancial damages to the company and its shareholders, the government settled the case by making the company promise to keep accurate records from then on and maintain the utmost corporate transparency. In addition, the company was assigned a court-appointed monitor, to make sure the company kept its records squeeky clean.

Meanwhile, investors were furious as the whole ordeal tarnished the company's image. However, it was the events that unfolded afterwards baffled investors and ultimately caused the removal of Peter Dolan as CEO. Recently, the company had been in negotiations to prevent the Canadian company Apotex from producing generic versions of its most popular drug - Plavix. Note that Plavix is the world's second most popular drug with sales of over $4 billion per year - it also accounts for 30% of BMY's revenues. The negotiation involved paying Apotex to halt production of the drug until 2011, when the drugs patents expire. However, BMY inexplicably abandoned its rights to triple damages should its patent prevail at trial. As a result (since Apotex faced no penalties), the market was instantly flooded with generic versions of Plavix. Analysts and investors were shocked and confused, while the company struggled with damage control. Now, federal antitrust prosecutors are investigating the sour deal while the court-appointed monitor recommended the removal of the officers responsible.

Shares of BYM moved higher by nearly 4% on the news today despite the fact that most of the damage had already been done. Now after the company's rollercoaster ride from $26 to $20 back to $24, there is speculation on the street that this may clear the way for a possible buyout. What happens as a result of the investigation remains to be seen; however, this is yet another example of just how illogical management can act.

Mr. Robert P. Cummins' days may finally be numbered as CEO of Cyberonics, Inc. (NDAQ:CYBX) as shareholders move in to control the Board. Some may wonder how he stayed in office this long; after all, he is the subject of an SEC investigation while his company's stock has lost more than 50% of its value this year alone. These same people would be shocked to learn that he is not only still in office, but he also received a new five year contract extension and a 50% pay raise!

So, just how much money is Mr. Cummins making? Well, he made the most money on June 15, 2004 when he and two other company officers netted a cool $2.5 million overnight – not bad for a day’s work! How is this possible, you ask? Well it turns out that the company just happened to receive a favorable FDA report with regards to their flagship product the day of their stock option grant. While trading was halted for the rest of us at $19.58 per share (the prior day’s closing price), they were issued 170,000 options at this price while the press release was circulated. The next day the stock opened at $34.81 per share – netting a whopping $2,589,100 overnight! Unfortunately for them, the SEC took issue and they are currently still under investigation.

However, in addition to that “bonus”, Mr. Cummins has also made an estimated $17 million in proceeds on the sale of shares received through stock option grants in addition to a substantial grant of restricted shares. This is not to mention his $800,000 per year regular salary. In fact, the executive compensation was in such excess that one board member actually resigned, saying that he “cannot support the direction of the governance practices of the Cyberonics board, in particular its practices regarding CEO compensation and succession.”

While this man is minting his own money, investors are losing millions. Even now, when the company is facing delisting from the NASDAQ and a possible default on its senior notes, this man remains in control of the company. Fortunately, an activist hedge fund is seeking control of the Board to turn things around. You can read their letter to shareholders here, which outlines many of the issues addressed in this article. Whether they are successful or not is contigent on several factors; however, this story goes to show just how corrupt Corporate America can be.